Literature DB >> 8415583

Long survival with giant cell myocarditis.

H Ren1, R S Poston, R H Hruban, W A Baumgartner, K L Baughman, G M Hutchins.   

Abstract

Several aspects of giant cell myocarditis remain controversial, including the natural history of the disease and the nature of the giant cells. We have observed three patients who had long survival with chronic active giant cell myocarditis. The first patient was a 59-yr-old female who had a 10-yr history of complete heart block which was found at autopsy to have been caused by giant cell myocarditis. The second patient is a 36-yr-old female who received a heart transplant 5 yr after a biopsy proven episode of active myocarditis, and examination of the explanted heart revealed giant cell myocarditis. The third patient was a 41-yr-old male who received a heart transplant 2 yr after developing progressive heart failure, and the explanted heart had giant cell myocarditis. On immunohistochemical study of the three hearts, the giant cells stained with the macrophage markers lysozyme and KP-1 (CD-68). Staining of the same cells with desmin and actin was focally positive in a punctate pattern, correlating with the ultrastructural presence of myofibrils within giant cell phagolysosomes. The associated lymphocytic infiltrate stained primarily for the T-cell markers CD-3, CD-45RO, and CD-43 whereas only a few of the lymphocytes stained with the B-cell marker CD-20. The long histories of cardiac dysfunction in the three patients show that giant cell myocarditis may have a protracted course. The morphologic studies show that the giant cells are of histiocytic origin but can contain phagocytosed components of myocytes, observations that may account for the controversy surrounding the nature of the giant cells in giant cell myocarditis.

Entities:  

Mesh:

Year:  1993        PMID: 8415583

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  8 in total

Review 1.  Current treatment options in (peri)myocarditis and inflammatory cardiomyopathy.

Authors:  B Maisch; S Pankuweit
Journal:  Herz       Date:  2012-09       Impact factor: 1.443

2.  Fatal giant cell myocarditis after resection of thymoma.

Authors:  P E Glennon; M E Petersen; M N Sheppard
Journal:  Heart       Date:  1996-05       Impact factor: 5.994

Review 3.  Standard and etiology-directed evidence-based therapies in myocarditis: state of the art and future perspectives.

Authors:  Bernhard Maisch; Sabine Pankuweit
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

4.  Thymoma associated with fatal myocarditis and polymyositis in a 58-year-old man following treatment with carboplatin and paclitaxel: A case report.

Authors:  Hidefumi Sasaki; Motoki Yano; Osamu Kawano; Yu Hikosaka; Yoshitaka Fujii
Journal:  Oncol Lett       Date:  2011-11-30       Impact factor: 2.967

Review 5.  Idiopathic giant cell myocarditis and cardiac sarcoidosis.

Authors:  Lori A Blauwet; Leslie T Cooper
Journal:  Heart Fail Rev       Date:  2013-11       Impact factor: 4.214

6.  Treatment of Fulminant Giant Cell Myocarditis Associated with Polymyositis Using a Left Ventricular Assist Device and Subsequent Corticosteroid and Immunosuppressive Therapy Leading to Remission.

Authors:  Junichi Ooka; Hidekazu Tanaka; Yutaka Hatani; Yukio Tsuji; Ryo Takeshige; Shumpei Mori; Kensuke Matsumoto; Shigeo Hara; Hiroshi Tanaka; Yutaka Okita; Ken-Ichi Hirata
Journal:  Intern Med       Date:  2017-08-01       Impact factor: 1.271

7.  Idiopathic giant cell myocarditis or cardiac sarcoidosis? A retrospective audit of a nationwide case series.

Authors:  Kaj Ekström; Anne Räisänen-Sokolowski; Jukka Lehtonen; Hanna-Kaisa Nordenswan; Mikko I Mäyränpää; Markku Kupari
Journal:  ESC Heart Fail       Date:  2020-04-28

8.  Manifestations and Outcome of Cardiac Sarcoidosis and Idiopathic Giant Cell Myocarditis by 25-Year Nationwide Cohorts.

Authors:  Hanna-Kaisa Nordenswan; Jukka Lehtonen; Kaj Ekström; Anne Räisänen-Sokolowski; Mikko I Mäyränpää; Tapani Vihinen; Heikki Miettinen; Kari Kaikkonen; Petri Haataja; Tuomas Kerola; Tuomas T Rissanen; Jorma Kokkonen; Aleksi Alatalo; Päivi Pietilä-Effati; Seppo Utriainen; Markku Kupari
Journal:  J Am Heart Assoc       Date:  2021-03-04       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.